RADNOR, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT").
On February 20, 2024, RAPT issued a press release revealing that the FDA "has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma" and that RAPT "expects to receive a formal clinical ...
RAPT)>Full story available on Benzinga.com